U.S./EU Filings Position Bayer Compound As First Approval For CTEPH
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.
You may also be interested in...
New Products, Emerging Markets Spur Pharmaceutical Growth For Bayer
During its recent earnings call, the German conglomerate pointed to five drugs recently launched or now awaiting regulatory approval as driving its pharmaceutical sales growth from 2013 to 2015, along with strengthening performance in emerging markets.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.
Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market
Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.